Our Technology

From a small drop of blood to life-enhancing or life-saving results in under five minutes.

In this smartphone-enabled society, the patient is fast becoming a custodian of his or her own health. In the case of certain chronic conditions like diabetes, the implications are profound. For the first time, patients could be in the driving seat of diagnostic testing, with the ability to KNOW NOW a reality.

Diabetes testing:
the situation today

You might be thinking that people with diabetes already
self-test all the time. But there’s an important distinction between this daily blood glucose monitoring and a glycated hemoglobin test (HbA1c) or A1c test.

Testing blood sugar with a personal meter is commonplace but, crucially, it only provides a snapshot of day-to-day control. In contrast, the A1c test, the gold-standard in diabetes care, provides average blood glucose over the previous two or three months. It’s like comparing a still photo with a video montage.

The results of the A1c test give the doctor an accurate picture of how blood sugar has been managed over time, essential for managing a chronic disease like diabetes where adjustments to treatment need to be made in order to achieve optimal control.

Accurate A1c testing has traditionally been the domain of clinical laboratory testing. However, in recent years, clinical testing close to the site of patient care, known as point of care testing, has become more widespread. Bench-top instruments that use a finger-prick sample and are designed for use in a treatment room or at the bed-side may provide near immediate results but question marks remain over their accuracy and precision.1 Current A1c diagnostic testing risks falling behind modern patient and clinical demands, even at the point of care.

This is where dianax comes in.

The future of diabetes testing

dianax is producing a diagnostic laboratory shrunk into a revolutionary chip (lab-on-a-chip)* embedded in a disposable cartridge device. It is as small as a USB key and slots easily into any smartphone or tablet by means of a connecting adaptor or Bluetooth® connectivity. Ours is the first ever diagnostic test to combine microfluidics innovation, microelectrophoresis and electrochemistry.
Its innovative technology will provide a convenient and affordable means of accessing reliable, precise and accurate test results in under five minutes –
anytime, anywhere, for anyone.


Finger-prick blood sample introduced into the device. Sample moved through the microfluidics circuits by capillarity using MEMS** technology


Sample preparation and electrophoresis purification (to extract the proteins from the sample)


Electrochemical detection (to measure the concentration of the target proteins)


Data processed and displayed on a smartphone, a tablet or a standard PC and relayed to the treating physician in real time (Cloud connectivity)


By miniaturizing tests into a mobile pathology lab that patients can use at the POINT OF NEED, physicians will be better equipped to make more rapid and informed treatment decisions. And it doesn’t just benefit the patient and improve their prognosis. The ability to KNOW NOW also has potential to reduce downstream costs.2

*Products/devices are under development but not yet approved for use. For investigational use only. Design subject to change and further enhancements.
**Micro-Electro-Mechanical Systems or MEMS

1.     Hirst J, et al. Clin Chem Lab Med 2017;55(2):167–180 https://www.degruyter.com/downloadpdf/j/cclm.2017.55.issue-2/cclm-2016-0303/cclm-2016-0303.pdf
[Accessed 10 Dec 2017]

2.     El-Osta A, et al. BMJ Open 2017;7:e015494 http://bmjopen.bmj.com/content/bmjopen/7/8/e015494.full.pdf   [Accessed 10 Dec 2017]